The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration

Pediatric Diabetes

Volumn 19, Issue 1, 2018, Pages 14-17

  Messer, Laurel H ^a   Forlenza, Gregory P ^a   Wadwa, R Paul ^a   Weinzimer, Stuart A ^b   Sherr, Jennifer L ^b   Hood, Korey K ^c   Buckingham, Bruce A ^c   Slover, Robert H ^a   Maahs, David M ^c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ANTIDIABETIC AGENT;

AUTOMATION; CONCEPTUAL FRAMEWORK; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; HUMAN; INSULIN TREATMENT; NOTE; PEDIATRICS; PRIORITY JOURNAL; ARTIFICIAL PANCREAS; INSULIN INFUSION;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL;

EID: 85021370189     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12535     Document Type: Note

References (24)

1. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care. 2015;38:1036-1043.
2. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11 suppl 1:S113-S119.
3. Doyle FJ 3rd, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial pancreas systems: engineering the algorithms. Diabetes Care. 2014;37:1191-1197.
4. Pinsker JE, Lee JB, Dassau E, et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care. 2016;39:1135-42.
5. Ly TT, Weinzimer SA, Maahs DM, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatr Diabetes. 2016. doi: 10.1111/pedi.12399. [Epub ahead of print].
6. Kropff J, DeVries JH. Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther. 2016;18 suppl. 2:S253-S263.
7. Thabit H, Hovorka R. Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia. 2016;59:1795-805.
8. Battelino T, Omladič J, Phillip M. Closed loop insulin delivery in diabetes. Best Pract Res Clin Endocrinol Metab. 2015;29:315-325.
9. Blauw H, Keith-Hynes P, Koops R, DeVries JH. A review of safety and design requirements of the artificial pancreas. Ann Biomed Eng. 2016;44:3158-3172.
10. Forlenza GP, Buckingham B, Maahs DM. Progress in diabetes technology: developments in insulin pumps, continuous glucose monitors, and progress towards the artificial pancreas. J Pediatr. 2016;169:13-20.
11. Cherñavvsky DR, DeBoer MD, Keith-Hynes P, et al. Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus. Pediatr Diabetes. 2016;17:28-35.
12. DeBoer MD, Cherñavvsky DR, Topchyan K, Kovatchev BP, Francis GL, Breton MD. Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes. 2016. doi: 10.1111/pedi.12454
13. Forlenza G, Chernavvsky D, DeBoer M, et al. The artificial pancreas (AP) improves glycemic control during extended exercise at ski camp in adolescents with type 1 diabetes (T1D). Diabetes Technol Ther. 2017;19:A47.
14. Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33:1013-1017.
15. Maahs DM, Calhoun P, Buckingham BA, et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37:1885-1891.
16. Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care. 2014;37:3025-3032.
17. Tauschmann M, Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living. Randomized Clinical Trial. Diabetes Care. 2016;39:1168-1174.
18. Cameron F, Baysal N, Buckingham BA, et al. Hotel trial of a fully closed-loop artificial pancreas with unannounced, unscheduled large meals. Diabetes. 2016;65(suppl1):A256.
19. Forlenza GP, Cameron F, Baysal N, et al. Effect of meal detection suppression on postprandial glycemic excursion in fully closed-loop artificial pancreas with unannounced. unscheduled large meals. Diabetes. 2016;65(suppl1):A258.
20. Hamaki H. FDA approves minimed 670G system- world's first hybrid closed loop system. Meaningful Innovat. 2016. http://www.medtronicdiabetes.com/blog/fda-approves-minimed-670g-system-worlds-first-hybrid-closed-loop-system/. Accessed November 26, 2016.
21. National Institutes of Health. Four pivotal NIH-funded artificial pancreas research efforts begin. 2017. https://www.nih.gov/news-events/news-releases/four-pivotal-nih-funded-artificial-pancreas-research-efforts-begin. Accessed February 12, 2017.
22. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. J Am Med Assoc. 2016;316:1407-1408.
23. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38:971-978.
24. Messer L, Forlenza G, Wadwa RP, et al. Hybrid closed-Loop (HCL) therapy in adolescents and young adults with type 1 diabetes (T1D) increases time in range. Diabetes Technol Ther. 2017;19:A-13.